Abstract | For more than two decades, sepsis was defined as a microbial infection that produces fever (or hypothermia), tachycardia, tachypnoea and blood leukocyte changes. Sepsis is now increasingly being considered a dysregulated systemic inflammatory and immune response to microbial invasion that produces organ injury for which mortality rates are declining to 15-25%. Septic shock remains defined as sepsis with hyperlactataemia and concurrent hypotension requiring vasopressor therapy, with in-hospital mortality rates approaching 30-50%. With earlier recognition and more compliance to best practices, sepsis has become less of an immediate life-threatening disorder and more of a long-term chronic critical illness, often associated with prolonged inflammation, immune suppression, organ injury and lean tissue wasting. Furthermore, patients who survive sepsis have continuing risk of mortality after discharge, as well as long-term cognitive and functional deficits. Earlier recognition and improved implementation of best practices have reduced in-hospital mortality, but results from the use of immunomodulatory agents to date have been disappointing. Similarly, no biomarker can definitely diagnose sepsis or predict its clinical outcome. Because of its complexity, improvements in sepsis outcomes are likely to continue to be slow and incremental. NATURE REVIEWS | DISEASE PRIMERS VOLUME 2 | 2016 | 1 PRIMER © 2 0 1 6 M a c m i l l a n P u b l i s h e r s L i m i t e d . A l l r i g h t s r e s e r v e d .
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. Further described by Boerhaave, von Liebig, Semmelweis, Pasteur, Lister, Lennhartz and, most recently, Bone, sepsis and its treatment have confounded investigators for nearly 3,000 years. Since 1991, the consensus definition of sepsis has been the 'systemic inflammatory response (SIRS) to a microbial infection' (REFS 2,3) (BOX 1), with SIRS defined as at least two of the following: tachypnoea (rapid breath ing), tachycardia (rapid heartbeat), pyrexia (fever) or hypothermia, and leukocytosis, leukopaenia or neutro philia. Efforts have recently focused on eliminating the SIRS requirement entirely 4 (BOX 2) because fever, tachy cardia, tachypnoea and white blood cell changes reflect infection only and have proven to be too broadly applied in critically ill patients to be useful in the definition of sepsis. In its place, sepsis is now defined as an infection associated with organ injury distant from the site of infec tion. Septic shock remains defined as a subset of sepsis in which the risk of mortality is substantially increased, and is characterized by hypotension that persists during volume resuscitation and requires the use of vasopressors.
The study of sepsis treatment reflects progress in our understanding of human pathophysiology and hostmicroorganism interactions. Early research focused on the microorganism and its pathogenicity. In the 1980s, with the implementation of molecular cloning and the sequencing of human inflammatory genes, research in sepsis turned towards investigations that focused less on the pathogenicity of the microorganism and more on the host response to an invading pathogen [5] [6] [7] . The discov ery of how the host distinguishes self and nonself and the introduction of the 'danger hypothesis' (REF. 8 ) have dramatic ally improved our understanding of sepsis and its pathogenesis. The danger hypothesis purports that the innate immune system recognizes microbial patterns and unique host cellular products as 'danger signals' or 'alarmins' of microbial invasion or tissue injury. However, research has also revealed that the progression of sepsis is much more complex than just inflammation or microbial or host pattern recognition; sepsis also involves effects on endothelial tissues and microcirculation, primary and secondary immune tissues, coagulation, parenchymal tissues and neurological disturbances that directly affect microglial cells and neurons [9] [10] [11] [12] . Despite a dramatic increase in our understanding of sepsis, its origins, progression and resolution (recovery or death), our ability to intervene and alter the trajectory of the disease has been only partially successful. That is, our increased understanding of the pathogenesis of the disease has generally failed to substantially improve outcomes. Although inhospital mortality from sepsis has declined over the past decade 13 , this improvement is more commonly attributed to earlier recognition and better compliance with bestpractice supportive thera pies 14, 15 . In this Primer, we describe the contemporary definitions and the current epidemiological picture of sepsis and septic shock, as well as the best practices for the recognition and support of patients with sep sis and the use of potential biomarkers and biological response modifiers to better identify patients and treat them effectively.
Epidemiology

Incidence and prevalence
Despite its high associated mortality, comprehensive epi demiological data on the global burden of sepsis are lack ing. A tentative extrapolation of data from high income countries suggests that 31.5 million cases of sepsis and 19.4 million cases of severe sepsis occur globally each year, with potentially 5.3 million deaths annually 16 . These numbers are simply estimates because knowledge about the incidence and mortality of sepsis in lowincome and middleincome countries remains scarce owing to scant data and the difficulty of generating populationlevel esti mates in these regions [16] [17] [18] . Sepsis is also not tracked in the Global Burden of Disease report published by the WHO and World Bank, which monitor incidence, mortality and risk factors of the most important diseases in the world 19 . Given the high prevalence of infectious diseases associ ated with an increased risk of sepsis and septicaemia, such as HIV 20 , nontyphoid salmonella and Streptococcus pneumoniae 21 , a substantial burden of sepsis should be expected in regions affected by these diseases. Indeed, in 2013, lower respiratory tract infections ranked second among the leading causes of disabilityadjusted lifeyears and accounted for >2.5 million deaths globally, of which a considerable proportion could be considered sepsis 22 . Similarly, malaria and viral infections such as dengue are also major sources of systemic infections in low income and middleincome countries, with the majority of overall deaths attributable to sepsis 23 . Contemporary epidemiological studies from high income countries suggest high incidence rates of hospital treated sepsis, ranging from 194 per 100,000 inhabitants in Australia in 2003 (REF. 24) to 580 per 100,000 inhabit ants in the United States in 2006 (REF. 25 ). In Germany, the incidence of hospitaltreated sepsis cases between 2007 and 2013 increased from 256 to 335 cases per 100,000 inhabitants; the proportion of patients with severe sepsis increased from 27% to 41% 26 . Furthermore, for highincome countries, several pro spective and retrospective epidemiological studies have presented data on the incidence, point prevalence, period prevalence and mortality of sepsis. These reports have extrapolated their results to a population level; several have suggested dramatic increases in the occurrence of sepsis 27, 28 . However, interpretation of these findings is hampered by the fact that many of the studies use vari ous different methods and sepsis definitions, including the 1991 consensus criteria (BOX 1) or derivative WHO International Classification of Diseases (ICD) code abstractions for register studies. Indeed, many databases included the 1991 consensus criteria such that infection (typically characterized by fever and its accompanying tachycardia and an altered white blood cell count) and sepsis were often confounded. Accordingly, depending on the codes used to identify clinical sepsis, prevalence can differ substantially 29, 30 . For example, one study com pared four different methods of assessing sepsis using the same databases and showed that the incidence of sepsis varied more than threefold between methods 31 . Furthermore, the increased incidence of sepsis in some health care systems might be attributable to increased clinical awareness of sepsis and/or financial incentives for enhanced reimbursement for services by coding patients with sepsis. Thus, these variable definitions could explain the dramatic increase in the number of sepsis cases associated with a reduction in mortality rates in highincome countries.
Chartbased clinical validation of cases of sepsis identified through administrative databases has often revealed several fold higher incidence rates than observed in prospective or retrospective trials 27 . By contrast, other studies have suggested that, in administrative data from hospitals, septicaemia, sepsis and severe sepsis might not be coded correctly or missed 32, 33 . Accordingly, there is an ongoing controversy on the accuracy of coding itself, especially when sepsis is less severe 33, 34 . Furthermore, only hospitalized patients are included in these observa tional studies, whereas a considerable number of patients experience sepsis outside the hospital setting 35 . As such, concerns abound that recent epidemiological data from highincome countries are unable to capture the real bur den of sepsis, but there is little controversy that sepsis remains a considerable challenge in the developed world.
Mortality
Estimates of sepsis associated with inhospital mortality are equally confounded. Between 1999 and 2009, mor tality directly ascribed to sepsis seems to have declined on the basis of data obtained from death certifi cates or administrative databases. However, in many cases, especially in patients with chronic diseases such as cancer, congestive heart failure and chronic obstructive pulmonary disease, the official record of death often reports the underlying disease rather than the immedi ate cause of death (sepsis), which might contribute to the apparent underestimation in mortality from sepsis 35 . Data from Australia and New Zealand, in particular, have suggested that overall mortality rates attributable to sep sis are declining 13 . Although the percentages of patients with sepsis who are dying in the hospital are decreasing, Martin et al. 28 and Gaieski et al. 31 demonstrated that overall mortality rates tend to be increasing, due to the apparent increases in the number of patients with sepsis.
Whether mortality from septic shock is declining is less clear. Kaukonen et al. 13 reported from their admin istrative databases that mortality from septic shock has declined at rates comparable to those of sepsis. However, a cursory analysis of data from randomized controlled trials has suggested that, if mortality from septic shock is declining, it is doing so at a slower rate than for sepsis. The problem, in part, is that mortality rates from septic shock vary dramatically depending on the expertise and experience of the treating centre. In some countries, mortal ity from septic shock still approaches 50%, whereas in others, mortality is being reported at 20-30% 36 . The overall decreases in inhospital sepsis mortality, and possibly in septic shock, are encouraging. However, given that the overall incidence of sepsis is seemingly increasing at greater rates, overall mortality is not sig nificantly improving, demonstrating the continuing magnitude of the challenge.
Mechanisms/pathophysiology
Inflammation Sepsis is fundamentally an inflammatory disease mediated by the activation of the innate immune sys tem. Two key findings characterize the innate immune response in sepsis. The first finding is that sepsis is gen erally initiated by simultaneous recognition of multiple infectionderived microbial products and endogenous danger signals by complement and specific cellsurface receptors on cells whose primary job is surveillance 37 . These cells include immune, epithelial and endothelial populations that are physically located where they can continuously sample their local environment. Binding of both pathogenassociated molecular patterns (PAMPs) or damageassociated molecular patterns (DAMPs) to complement, Tolllike receptors, nucleotidebinding oligomerization domain (NOD)like receptors, retinoic acidinducible gene (RIG)like receptors, mannose binding lectin and scavenger receptors, among others, induces a complex intracellular signalling system with redundant and complementary activities 38 (FIG. 1) .
The second key finding in sepsis is that activation of these multiple signalling pathways ultimately leads to the expression of several common gene classes that are involved in inflammation, adaptive immunity and cellular metabolism. That is, the recognition of many different components of bacteria, viruses and fungi, as well as host products of tissue injury, leads to the recruitment of proinflammatory intermediates that in turn result in the phosphorylation of mitogen activated protein kinases (MAPKs), Janus kinases (JAKs) or sig nal transducers and activators of transcription (STATs) and nuclear translocation of nuclear factorκΒ (NFκΒ), to name simply a few. These intermediates initiate the expression of early activation genes. Taken together, these two characteristics of innate immunity assure a common response pattern, the intensity and direction of which can be finely regulated by the level of and vari ation in the repertoire of PAMPs and DAMPs and the signalling pathways activated. This complementary nature of the pathways explains the overlapping but unique early inflammatory response to common Gram negative bacterial, Grampositive bacterial, fungal and viral infections and tissue injury.
Early activation genes. Nuclear translocation of NFκB and activation of its promoter in particular induce the expression of multiple early activation genes, includ ing cytokines that are associated with inflammation (including tumour necrosis factor (TNF), IL1, IL12, IL18 and type I interferons (IFNs)). These cytokines initiate a cascade of other inflammatory cytokines and chemokines (including IL6, IL8, IFNγ, CCchemokine ligand 2 (CCL2), CCL3 and CXCchemokine ligand 10 (CXCL10)), as well as the polarization and suppression of components of adaptive immunity. The activation of these inflammatory networks begins within minutes of PAMP or DAMP recognition owing to the exist ence of preformed inactive and active cytokine pools. Simultaneously, activation of these sentinel innate immune receptors, activation of complement and/or production of inflammatory cytokines have a profound effect on coagulation and the vascular and lymphatic endothelium, resulting in the increased expression of selectins and adhesion molecules 39 . The alteration in the expression of various procoagulant and anti coagulant proteins, including thrombomodulin, tissue factor, von Willebrand factor, plasminogen activator inhibitor 1 (PAI1) and activated protein C, results in the transition of the endothelium from an anticoagu lant state (in health) to a procoagulant state (in sepsis). Proinflammatory proteases induce the internalization of the vascular endothelial (VE)cadherin leading to the loss of endothelial tight junctions and increased vascular permeability 40 .
Box 1 | 1991 criteria for sepsis, severe sepsis and septic shock
The following definitions derive from the 1991 Consensus Conference of the American College of Chest Physicians and Society of Critical Care Medicine 2, 162 . Infection is defined as the presence of microorganisms or tissue invasion by those microorganisms.
Sepsis
The systemic inflammatory response (SIRS) to infection, manifested by at least two of: • Temperature of >38 °C or <36 °C • Heart rate of >90 beats per minute • Respiratory rate of >20 breaths per minute or partial pressure of CO 2 of <32 mmHg • White blood cell count of >12,000 per ml or <4,000 per ml, or >10% immature (band) forms
Severe sepsis
Severe sepsis is defined as sepsis associated with organ dysfunction, hypotension or hyperfusion. Hypoperfusion abnormalities of end organs may include lactataemia, oliguria or an alteration in mental status.
Septic shock
Septic shock is defined as sepsis associated with hypotension and perfusion abnormalities despite the provision of adequate fluid (volume) resuscitation. Perfusion abnormalities include lactic acidosis, oliguria or an acute alteration in mental status. Patients with septic shock who are receiving inotropic or vasopressor therapy might still exhibit perfusion abnormalities, despite the lack of hypotension.
The C5a-C5a receptor axis Complement activation is considered to be one of the hallmarks of sepsis and is initiated immediately upon exposure to PAMPs and DAMPs. Complement activ ation leads to the generation of complement peptides (namely, C3a and C5a). C5a has been shown to be one of the most active inflammatory peptides produced during sepsis 41 and is one of the most potent chemo attractants for neutrophils, monocytes and macro phages. In neutro phils, C5a triggers an oxidative burst leading to the generation of reactive oxygen species and the release of granular enzymes, which are thought to be crucially involved in inflammatory tissue damage. Furthermore, C5a is a stimulant for the synthesis and release of pro inflammatory cytokines and chemo kines, thereby amplify ing inflammatory responses. These mechanisms are believed to contribute to vaso dilation, tissue damage and multiple organ failure in settings of acute inflam mation. The potential role of C5a in the development of sepsis has been linked to neutrophil dysfunction, apop tosis of lymphoid cells, exacerbation of systemic inflam mation, cardiomyopathy, disseminated intra vascular coagulation (DIC) and complications associated with multiple organ failure 42 . Blockade of C5a in experimental models of sepsis has been shown to be beneficial in various models from different groups. For example, inhibition of C5a by rabbit polyclonal antibodies in a primate model of sepsis induced by infusion of live Escherichia coli sub stantially attenuated evidence of acute sepsisinduced lung injury and failure 43 . Similarly, the blockade of C5a with antibodies in rats or mice with sepsis caused by caecal ligation puncture was highly effective in dimin ishing the severity of sepsis and improving outcome 44, 45 . In addition, severe inflammatory responses and their associated organ damage during avian H5N1 and H1N1 viral infections have also been linked to complement activation, especially the overproduction of C5a 46, 47 . Along these lines, a monoclonal antibody raised against human C5a greatly attenuated H7N9induced lung damage in nonhuman primates, reducing the viral load and the levels of several different cytokines in this setting 48 . The same antibody is currently being tested in patients with early abdominal or pulmonary septic organ dysfunction 49 . 4 , which considers infection to be an interaction between a host and a pathogen that induces a local or systemic host response.
Immune suppression
Sepsis
• Life-threatening organ dysfunction owing to a dysregulated host response to infection • Onset marked by the beginning of any organ dysfunction remote from the site of infection
Septic shock
• A subset of sepsis in which underlying circulatory and cellular-metabolic abnormalities are profound enough to substantially increase mortality • Operationally defined as requiring vasopressor therapy to maintain a mean arterial blood pressure of >65 mmHg and an increased plasma lactate level of >2 mmol per l failure of monocytes to recover HLADR levels predicts a poor outcome from sepsis
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. Sepsis also causes both stro mal cells and professional APCs to increase the expres sion of the T cell protein programmed death ligand 1 (PDL1), which binds to the inhibitory programmed death protein 1 (PD1) receptor that is expressed by T cells, fur ther suppressing T cell function 65 . The combination of the increased surface expression of inhibitory T cell ligands by APCs, loss of activating MHC class II molecules and increased production of antiinflammatory cytokines skews the T cell phenotype towards an immuno suppressive T helper 2 (T H 2) phenotype, increases the suppressor activity of T regulatory cells and causes broad T cell anergy (lack of reaction) (FIG. 3) . Lending further support to the notion that immune suppression occurs in sepsis, proinflammatory and T H 1 cytokine production by lymphocytes from patients with sepsis is <10% of that of controls without sepsis 65 . Together, these data provide a mechanism for the welldescribed loss of the delayedtype hypersensitivity in patients with sepsis, a metric for the profound suppression of the adaptive immune system seen in sepsis 66 . An autopsy study of patients with sepsis identified apoptotic cell death as an underlying driver of innate and adaptive immunosuppression 67 . Indeed, patients with sepsis demonstrate a profound apoptotic loss of . Sepsis is initiated upon host recognition of pathogenassociated molecular patterns (PAMPs) and is characterized by the activation of inflammatory signalling pathways. A large number of cell-associated and intracellular receptors are available to detect PAMPs or damage-associated molecular patterns (DAMPs), a few examples of which are illustrated here. PAMPs and DAMPs can be microbial and host glycoproteins, lipoproteins and nucleic acids. The associated patternrecognition receptors include Toll-like receptors (TLRs), C-type lectin domain family 7 member A (dectin 1) and C-type lectin domain family 6 member A (dectin 2). At least ten different TLRs are known, and in many cases they exist as either homodimers or heterodimers. Once activated, the ensuing signalling pathways generally converge towards interferon regulatory factor (IRF) signalling and nuclear factor-κB (NF-κB). IRF is responsible for type I interferon (IFN) production. NF-κB and activator protein 1 (AP-1) signalling are predominately responsible for the early activation of inflammatory genes, such as TNF, IL1 and those encoding endothelial cell-surface molecules. CARD9, caspase recruitment domain-containing protein 9; dsDNA, double-stranded DNA; dsRNA, double-stranded RNA; FcRγ, Fcγ receptor; HMGB1, high-mobility group protein B1; iE-DAP, d-glutamyl-meso-diaminopimelic acid; LGP2, laboratory of genetics and physiology 2 (also known as DHX58); LPL, lipoprotein lipase; LPS, lipopolysaccharide; LY96, lymphocyte antigen 96; MAPK, mitogenactivated protein kinase; MCG, mannose-containing glyco protein; MDA5, melanoma differentiation-associated protein 5 (also known as IFIH1); MDP, muramyl dipeptide; MCL, mannose-capped lipoarabinomannan; Mincle, also known as CLEC4E; MYD88, myeloid differentiation primary response protein 88; NIK, NF-κB-inducing kinase (also known as MAP3K14); NOD, nucleotide-binding oligomerization domain; RAF1, RAF proto-oncogene serine/threonine-protein kinase; RAGE, advanced glycosylation end product-specific receptor; RIG-I, retinoic acid-inducible gene 1 protein (also known as DDX58); ssRNA, single-stranded RNA; STING, stimulator of interferon genes protein; SYK, spleen tyrosine kinase; TDM, trehalose-6,6ʹ-dimycolate; TICAM1, TIR domain-containing adaptor molecule 1.
T cells, B cells and dendritic cells, an observation that is recapitulated in animal models of sepsis 68 . Apoptotic loss of lymphocytes is directly immunosuppressive, contributing to the lymphopaenia observed in patients with severe sepsis 69 . The degree of lymphocyte apoptosis correlates with the severity of sepsis and the persistent lymphopaenia predicts sepsis mortality 70 . Apoptotic cells also suppress immune function through interaction with other leukocytes. For instance, phagocytosis of apoptotic lymphocytes causes the release of antiinflammatory cytokines such as IL10 and TGFβ from macrophages and dendritic cells. This process also suppresses the production of proinflammatory cytokines at the level of gene transcription, thereby contributing to the paraly sis of the innate inflammatory response in sepsis 70 . Accordingly, pharmacological or genetic manipulations that decrease sepsisinduced apoptosis improve survival in animal models of sepsis 68, [71] [72] [73] [74] [75] [76] . These data demonstrate the functional consequence of sepsisinduced apoptosis. The next generation of treatments being evaluated for sepsis includes therapies that target both lymphocyte apoptosis and sepsisinduced immunosuppression; the results of these studies are eagerly anticipated.
Endothelial barrier dysfunction
In addition to profound changes in host protective immunity, endothelial barrier function is an integral component of the sepsis response. A continuous endothelial barrier coats the vascular system and separ ates the fluid phase of the blood compartment from the tissues (FIG. 4) . Under normal resting conditions, the endothelium serves as an anticoagulant surface that regulates the flow of gases, water, solutes, hormones, lipids, proteins and a multitude of other macro molecules within the microcirculation. Sepsis is now viewed as a dysregulation of the interacting and oscillating circuitry networks of cell-cell communication that maintain homeostasis under normal conditions 9 . Along these lines, endothelial barrier dysfunction is a fundamental pathophysiological event that occurs early in sepsis and septic shock in particular. The border between the blood and the interstitium is highly interactive and dynamic in both health and disease, with the endothelial cell as the principal regulatory cell type 11 . The endothelium func tions to cover the underlying capillary basement mem brane and adventitia to avoid exposing collagen fibres and tissue factor primarily to von Willebrand factor and factor VII. Collagen can immediately fix and poly merize von Willebrand factor, which activates platelets via glyco protein 1β; at the same time, exposing tissue factor to circulating factor VII can initiate clotting via the tissue factor (formerly known as the extrinsic) pathway 77 . The integrity of the endothelium is maintained by the cell cytoskeleton (actin), intercellular adhesion mol ecules (tight junctions) and an array of supportive pro teins. In sepsis, these structures are disrupted primarily in response to platelet and neutrophil adhesion, the release of inflammatory mediators and toxic oxida tive and nitrosative intermediates. Combined with the increased expression of selectins and integrins, binding of leukocytes to the endothelial surface results in the leakage of vascular fluid and migration of extravasating leukocytes across the compromised endothelial barrier. This event also provides the opportunity for collagen polymerization and tissue factormediated clotting to occur. Although these responses enable platelets and immune cells to reach tissue sites in response to trauma or localized infection, sepsis produces generalized, excessive and prolonged responses that can lead to considerable tissue injury.
In addition, the glycocalyx is a glycoproteinpolysaccharide layer that covers the endothelium and supports the anticoagulant state and maintains tight 165 in the 1990s, the current model of the clinical trajectory that patients traverse in sepsis has evolved to reflect the concurrent inflammatory and immunosuppressive responses, and the observation that fewer patients are dying in the early period owing to earlier recognition and better implementation of best clinical practices 50 . Successful resuscitation is occurring more frequently and the patients recover sufficiently to be discharged from the intensive care unit and hospital (blue lines). Some patients experience a pronounced early inflammatory response to the pathogen or danger signals, leading to multiple organ failure and death (red line). Other patients survive the early inflammatory response but experience chronic critical illness (green lines) that is characterized by persistent inflammation, immunosuppression and catabolism syndrome (PICS); reactivation of latent viral infections; nosocomial infections; and long-term functional and cognitive declines 52 . DAMP, damage-associated molecular pattern; DC, dendritic cell; MDSC, myeloid-derived suppressor cell; NO, nitric oxide; ROS, reactive oxygen species; T H 2, T helper 2.
junctions. Sepsis alters the continuity of the glycocalyx, which also increases endothelial permeability 78 . In sep sis, the glycocalyx is a target for inflammatory mediators and leukocytes because it is imbedded with endothe lial cellsurface receptors. The widespread presence of the glycocalyx in organ microvasculature can explain the endothelial activation and damage of tissues distant from the original site of infection via this systemic release of cytokines and other inflammatory mediators during sepsis. Inflammatorymediated injury to the glycocalyx contributes to acute kidney injury, respiratory failure and hepatic dysfunction.
Numerous factors regulate the expression of tight junction linkers and actin polymer networks. Prominent among these regulators are the relative expression of two competing intracellular, G proteinlinked GTPases known as RHOA and RAC1. RHOA generally induces actin filament breakdown and internalizes VEcadherin, resulting in endothelial barrier breakdown. RAC1 signalling has opposing effects, stabilizing the actin cytoskeleton and preventing apoptosis. The relative con centrations of RHOA and RAC1 can be regulated, at least experimentally, by proteaseactivated receptors (PARs) on endothelial surfaces. Early thrombin generation in sepsis activates PAR1, which promotes RHOA GTPase signalling and induces endothelial barrier breakdown. Other proteases that activate PAR2 promote RAC1 sig nalling and support endothelial barrier protection 79 . TABLE 1 lists some of the candidate therapies that might prove to be effective in maintaining and reacquiring endothelial barrier function in sepsis and septic shock.
The leaky capillary membranes create massive loss of intravascular proteins and plasma fluids into the extravascular space. Diffuse vasodilation throughout the microcirculation alters capillary blood flow, which contributes to poor tissue perfusion and -ultimately -shock. In septic shock, events within tissue capillaries induce distributive shock in which the recovery of blood pressure is not achieved upon the administration of addi tional intravenous fluids, and requires a vaso constrictive agent such as noradrenaline and/or vasopressin. The large volumes of crystalloid given to maintain central blood pressure in the presence endothelial injury frequently leads to oedema. 
Coagulation
In sepsis and septic shock, the normal anticoagulative state within the vasculature is disrupted. Sepsis results in a hypercoagulable state that is characterized by microvascular thrombi, fibrin deposition, neutrophil extracellular trap (NET) formation and endothelial injury. Inflammatory cytokines as well as other medi ators, such as plateletactivating factor and cathepsin G, target the endothelium and platelets. Platelet activation can itself propagate both coagulation and the inflam matory response by forming aggregates that can activ ate thrombin release. Thrombin is a serine protease that converts fibrinogen into insoluble strands of fibrin, as well as catalysing many other coagulationrelated reactions. These strands of fibrin, along with plate lets, provide the structural integrity to clot formation. In addition, inflammatory cytokines can promote coagulation by targeting the endothelium and causing endothelial injury (FIG. 5) .
The damaged endothelium and exposure of the underlying collagen activate von Willebrand factor, which further activates platelet aggregation and fibrin formation. Platelets might also trigger inflammation by activating dendritic cells. The activated endothelium also upregulates tissue factor, which can act directly on cir culating factor VII, leading to tissue factor-factor VIIa complexes that convert factor X to factor Xa, result ing in thrombin generation, fibrin deposition, contact factor activation, clot formation, bradykinin synthesis and complement activation. Furthermore, comple ment activation feeds back to promote further clotting through complementmediated shedding of cellderived microvesicles. These microvesicles from monocytes and macrophages contain additional tissue factor, thereby exaggerating inflammation and thrombosis 80 . Complement deposition on erythrocytes triggers haemolysis and the release of erythrocytederived microvesicles that are prothrombotic 81 . The resulting interaction between tissue factor and factor VIIa propa gates the inflammatory process and leads to fibrin depo sition on the endothelium. Microthrombi deposition, especially in the microvasculature, leads to decreased per fusion and thrombus formation. Concordantly, coagu lation augments inflammation predominantly through a thrombininduced secretion of pro inflammatory cytokines and growth factors. Extracellular tissue factor signalling through PARs elicits cellular activation and inflammatory responses antithrombin and activated protein C concentrations decrease, as does endothelial glycosaminoglycans, such as heparan sulfate 83 . Inhibition of both thrombo modulin and endothelial cell protein C receptor contributes to the decrease in activated protein C concentrations 84 . Simultaneously, fibrinolysis is dramatically decreased. Increased levels of PAI1 inhibit both tissue plasmino gen activator (tPA) and urokinase plasminogen activa tor (uPA). This dysregulation of the PAI1-tPA-uPA network results in a substantial reduction in the con centration of plasmin, which is required for dissolving intravascular fibrin clots. Thrombin generation and its binding to thrombomodulin activate thrombin activatable fibrinolysis inhibitor -further reducing plasmin generation.
Ultimately, this exaggerated coagulopathy can lead to uncontrolled bleeding. This event might seem incon sistent with the previous statements regarding a sepsis induced hypercoagulation and fibrin deposition, but the process is thought to occur secondary to a consumptive thrombocytopaenia and depletion of clotting factors 10 . The transition from a hypercoagulable state to DIC is characterized by fibrinolysis with increased circulating fibrin degradation products, thrombocytopaenia and exhaustion of liverderived prothrombin, fibrinogen, factor X and factor V reserves.
Clot formation. Inflammation and coagulation are tightly linked defence mechanisms following injury and autoamplify by costimulation 85 . In an anticoagu lant state during health, endothelial cells generally do not express adhesion molecules that bind to leukocytes and platelets, but will do so in sepsis in response to the early inflammatory response, resulting in the activation of coagulation. The local cytokine milieu in this stage of inflammation induces cellsurface receptors for myeloid cells, lymphocytes and platelets. Platelets bind to fibrin strands and provide a ready source of Pselectin for neutro phil attachment; activated neutrophils produce NETs that provide a scaffold for more clot formation and this process selfamplifies 10, 86 . This cooperative inter action serves to 'wall off ' sites of injury from the rest of the host, limiting infection risk. The clot also serves to avoid blood loss and possible exsanguin ation by plugging the defect in the vascular system. This co regulated clot formation and innate immune activation has an obvious survival advantage when a limited site of injury can be contained locally. However, if general ized activation of coagulation and inflammation occurs throughout the host, such as during DIC, the conse quences can be devastating and lead to potentially lethal septic shock (see below).
Effect on organ systems
Sepsis is also a systemic disorder that can affect all organs of the body, probably owing to the panoply of cytokines and other mediators that are released into the general circu lation during the onset of the dis order. The presenting signs and symptoms of sepsis are vari able and depend on the particular organ systems that are affected. Six types of organ dysfunction predomin ate in sepsis: neurological (altered mental status), pulmo nary (with hypoxaemia), cardiovascular (shock), renal (oliguria and/or increased creatinine concentra tion), haematological (decreased platelet count) and hepatic (hyperbilirubinaemia).
Neurological. Patients typically present with altered mental status manifested by lethargy, confusion or delirium. Occasionally, the mental status of the patient is so severely depressed that it is necessary to secure their airway (that is, perform endotracheal intubation). Despite this, the neurological examination at this time is typically without focal neurological findings. In the assessment, other causes of neurological disturbance (for example, hypoxaemia, hypoglycaemia, drug tox icity or central nervous system infection) should be ruled out or if present, addressed. 
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Inflammation-coagulation-bleeding amplification cycle Figure 5 | Interaction between coagulation and inflammation. Microorganisms and damage-associated molecular patterns (DAMPs), as well as complement activation and the release of inflammatory cytokines or mediators, can initiate the coagulation cascade (involving the coagulation factors designated here as 'F' followed by the requisite Roman numeral). Primarily through the upregulation of procoagulant proteins such as tissue factor (TF), excessive fibrin deposition and reduced plasmin activity lead to thrombus and fibrin deposition and microcirculatory defects. The system is self-activating as complement activation and the exposure of myeloid and endothelial cells to microbial products and inflammatory cytokines increase the expression of TF. Products of complement activation, such as C3a and C5a, induce platelet-activating factor (PAF; not shown) and inflammatory cytokines. Cytokines, PAF and thrombi can also damage the endothelium, exposing collagen fibres and activating von Willebrand factor (vWF), which further increases TF expression and inflammatory cytokine production. Although not shown here, inflammatory cytokines also decrease the expression of the fibrinolytic pathway, by increasing plasminogen activator inhibitor 1 (PAI-1) activity and decreasing plasmin activity. DIC, disseminated intravascular coagulation; MBL, mannose-binding lectin.
Oxidative and nitrosative stress (the buildup of reactive oxygen and nitrogen species, respectively) also contribute to cardiovascular and other organ fail ure, which is one of the root causes of tissue hypoxia 88 . Nitrosative stress is a major component of the patho physiology of sepsis, and upregulation of inducible nitric oxide synthase (iNOS) might provide the link between inflammatory activation and cardio vascular compromise. In this context, the role of hypoxia induced factorα (HIFα) in sepsis also plays a major part in defining its pathophysiology 89 .
Renal. Renal dysfunction that progresses to frank renal failure is a major cause of sepsisinduced mor bidity 12 . Although the exact mechanisms responsible for sepsis induced renal failure are unknown, clinicians can reduce the incidence of severe renal failure in sepsis by aggressive and appropriate volume resuscitation in the disorder. Because of loss of intravascular volume in sepsis due to leaky capillary membranes and vaso dilation, patients typically require volume resuscitation to replace these losses. Accordingly, clinicians must avoid the use of nephrotoxic agents in patients with sepsis if at all possible. For example, administration of intravenous contrast agents for radiological imag ing studies can precipitate newonset renal failure if given to a patient with sepsis who is intravascularly volume depleted. The absence of full renal recovery in sepsis is associated with poor longterm outcomes, so management of renal function during sepsis is of crucial importance. Even minor increases in the con centrations of serum creatinine are associated with increased mortality 90 .
Haematological. DIC is one of the most striking manifest ations of severe sepsis. DIC can present in one of two contrasting clinical fashions: with overt bleed ing from multiple sites or, conversely, with thrombosis of small and medium blood vessels. The reason for the striking differences in presentation of DIC is attribut able to the fact that the coagulation system represents a balance between the clotting and fibrinolytic systems.
In individ ual cases of sepsis, either system can pre dominate. If the fibrinolytic system is dominant, the patient will present with bleeding from multiple sites. Conversely, if the coagulation system is dominant, the patient will present with cyanotic (discoloured) fingers and toes that may progress to frank gangrene of the dig its or upper and lower extremities. It is imperative to rule out heparininduced DIC, which may masquerade as sepsisinduced DIC.
Hepatic. Liver dysfunction is common in sepsis, whereas sepsisinduced acute liver failure is rare, occurring in <2% of patients 91 . Sepsisinduced liver injury is indicated by increased concentrations of serum alanine transaminase and increased levels of bilirubin. The exact aetiology of liver dysfunction in sepsis is unknown. Undoubtedly, a large part of liver dysfunction in patients with septic shock is due to centrilobular necrosis of the liver secondary to poor hepatic perfusion. Autopsy studies of patients who died of sepsis have shown necrotic hepatocytes in the regions surrounding the central veins 65, 67 . In addition to necrotic cell death in the livers of patients with sep sis, hepatocytes have also been observed to be undergo apoptotic cell death 65, 67 . Interestingly, electron micro scopy has shown that there are increased autophagic vacuoles present within hepatocytes from patients with sepsis. In rare cases, autophagic vacuoles were so extensive as to be consistent with autophagyinduced cell death 92 . Thus, it seems that hepatocytes undergo multiple different types of cell death in sepsis.
Diagnosis, screening and prevention
Defining sepsis
No single diagnostic test is (and will ever be) available that establishes the diagnosis of sepsis or septic shock. Sepsis and septic shock are clinical syndromes defined by a constellation of signs, symptoms, laboratory abnor malities and characteristic pathophysiological derange ments. Clinicians often use these terms in an imprecise manner, which adds to the confusion when describing what is meant by the term sepsis. The 1991 SIRS criteria
, which include parameters on temperature, heart rate and white blood cell count, have proven to be rather difficult to translate into clinical practice or even use effectively as entry criteria for clinical trials of sepsis. Using the SIRS criteria plus infection as the defin ition of sepsis could be applied to a large percent age of patients who are admitted with uncomplicated infections for whom the label of 'sepsis' seemed out of place or irrelevant. For example, most children with middle ear infections will often have two or three SIRS criteria (fever, tachycardia and leukocytosis); to con sider them as 'septic' based on the SIRS criteria makes no clin ical sense, especially when most are prescribed oral anti biotics for treatment at home. Similarly, in a large number of patients, especially those in whom antibiotics have been started empirically, the detection of bacteria in the blood or bodily fluids is often prob lematic. In as many as 30% of the cases of presumed sepsis, no pathogen is ever identified. In many cases, evidence of infection is inferred radiologically or from haematological measurements 93 . The aforementioned proposed 2015 approach to the diagnosis of sepsis and septic shock is based on clinical realities and easily obtainable physiological and lab oratory parameters 4 
. What dis tinguishes sepsis from an otherwise localized microbial infection is that the host response is dysfunctional, general ized and contributes to multiple organ dysfunction and potentially septic shock 94 . Furthermore, sepsis is characterized by organ dysfunction in tissues that are not directly involved with the infectious process itself. A quick bedside assessment of organ injury has been proposed using readily available clinical measurements 95 . Indeed, early evidence of septic shock is manifested by hypoperfusion of tissues with resultant dysfunction and eventually by organ failure that occurs simultaneously or closely following the inflammatory event 96 .
Defining septic shock
Conceptually, septicaemia refers to sepsis with positive blood cultures, although it is an archaic term that is generally avoided. Blood cultures are not commonly positive, in part because bacteria do not need to cir culate in the bloodstream to induce sepsis, and in part because some patients are being treated empirically with antibiotics at the time of testing and before the diagnosis. Thus, the term septicaemia has been aban doned. The term 'septic shock' remains current and is defined as a state in which sepsis is associated with cardiovascular dysfunction manifested by persistant hypotension despite an adequate fluid (volume) resusci tation to exclude the possibility of volume depletion as a cause of hypotension. Hypotension is operationally defined as the requirement for vaso pressor therapy to maintain a mean arterial pressure of >65 mmHg and a plasma lactate level of >2 mmol per l. An increased level of serum lactate is a hallmark of tissue hypo perfusion and septic shock, and is helpful in early diagnosis. The usual cutoff value for an abnormally high lactate level is ≥2 mmol per l, but Casserly et al. 97 have recom mended the use of a lactate level of ≥4 mmol per l for inclusion in sepsis clinical trials.
Biomarkers
The ability of biomarkers to identify the presence and severity of sepsis has generally been limited. Many biomarkers based on the magnitude of the inflam matory response, such as IL6, IL10, CCL2, CXCL10 and HMGB1, have shown good correlation with the severity of sepsis and clinical outcome in population based studies, but have proven less useful for individ ual patients -in large part because of the lack of specifi city of the biomarkers and the commonality of the early inflammatory response. Our ability to distin guish sepsis from noninfectious critical illness and to prognosticate outcome is very limited.
The one exception is in the use of procalcitonin to distinguish sepsis from noninfectious critical illness and to guide the use of antibiotic therapy 98 . Procalcitonin is a peptide precursor of the hormone calcitonin that is produced by parafollicular cells of the thyroid and by the neuroendocrine cells of the lung and the intestine. In healthy individuals, procalcitonin levels are nearly undetectable. Initially, there was consider able enthusiasm that procalcitonin concen trations could distinguish sepsis from nonseptic crit ical illness and to predict clinical outcomes better than inflammatory cytokines or clinical criteria. Although controversial, the general consensus to date is that pro calcitonin is not an effective diagnostic measurement to rulein or ruleout sepsis or bacterial infection, or for prognostication, in the absence of additional clin ical data 98, 99 . However, this notion has been chal lenged by the findings of a recent multicentre study in >1,500 critically ill patients with presumed bacterial infections and sepsis. In this study, the duration of anti biotic treatment, 28day mortality and 1year mortality were significantly lower in the procalcitoninguided group than in patients who were managed without the procalcitonin measurement 100 . Furthermore, two recent large metaanalyses of data from patients with respiratory infections showed that procalcitonin to guide antibiotic treatment in patients with respiratory infections was not associated with higher mortal ity rates or treatment failure 101, 102 . Antibiotic use was significantly reduced across different clinical settings and diagnoses.
Prevention
Prevention of sepsis and septic shock is based on good clinical practices to reduce the incidence of infections, particularly in highrisk populations. In the community setting, prevention is centred on vaccination for atrisk populations, such as for pneumococcal pneumonia in the elderly and meningococcal infections in adoles cents and young adults. Other highrisk populations include those with advancedstage cancer, type I dia betes, endstage renal disease, congestive heart failure and chronic obstructive pulmonary disease
. Prevention in this group of individuals entails good hygiene, maintaining mobility and reducing frailty, pre serving nutritional status and adequately treating local wound infections.
Hospitalized patients pose a much greater challenge to sepsis prevention because of their concordant illness and an environment rich in pathogens. In this case, reducing primary length of stay and minimizing the frequency and duration of invasive procedures that dis rupt natural barriers are often some of the most effective tools. Simple hand washing, use of devices containing antimicrobials and frequent changing of catheters can reduce incidence 103 . Equally important in the hospital setting is constant surveillance and immediate interven tion to prevent sepsis and its progression to septic shock and multiple organ failure.
The US Agency for Healthcare Research and Quality has identified sepsis to be the most expensive condi tion treated in hospitals in the United States, with annual costs exceeding US$20 billion. Moreover, the US Centers for Medicare and Medicaid Services has imposed substantial financial penalties to hospitals and institutions that fail to adequately recognize and treat sepsis early. Most major academic hospitals use early warning systems to detect early infections and their systemic manifestations. These measures often include evaluation of haemodynamics, urine output, body temperature and mental function -often on an hourly basis. For suspicion of sepsis, early interven tion by adequately trained health care providers using broadspectrum antibiotics and fluid support, often necessitating a transfer to an intensive care unit (ICU), have been shown to result in significant reductions in mortality 14, 15 .
Management
Once sepsis is identified, early and aggressive appro priate management is a priority -the timing of which is crucial. Treatment is based on three components: infection control, haemodynamic stabilization and modulation of the septic response.
Infection control
The first priority in treatment is early adequate anti microbial administration and source control. Once a diagnosis of sepsis is suspected, a thorough search for a likely source must be conducted; clinical symptoms and signs, appropriate microbiological cultures and relevant imaging techniques must be used to try and determine the infectious source.
Adequate antimicrobial medication must be started as soon as possible and must not be delayed until culture data are obtained. The importance of initial appropriate antimicrobials has been well recognized given that it significantly reduces mortality risk 104, 105 . Patients should be given broadspectrum antimicrobial therapy that will cover all likely organisms, based on the likely source of infection, local microbiological flora and resistance patterns, recent antimicrobial therapy and health care facility ecology. Combination antimicrobial treatment is preferred to singleagent therapy, especially in the most severe cases 106, 107 . Once culture results are avail able, the choice of antimicrobials should be re evaluated, and deescalation to a narrower spectrum should be per formed whenever possible. This approach will opti mize treatment efficacy, limit toxicity, help to prevent the development of drug resistance and reduce costs. Nevertheless, in some cases, several organisms are incriminated, and, in as many as 30% of patients, culture results will be negative 108, 109 such that deescalation is not always warranted 110 . The recommended doses for many of the antimicro bials used in patients with sepsis are derived from noncritically ill patients or healthy volunteers. However, the pharmacodynamics and kinetics of many drugs could be altered in critically ill patients, especially in those with renal and hepatic dysfunction; therapies such as haemodialysis and haemofiltration can also influence drug distribution and clearance, necessitating dose adaptation. If available, daily monitoring of anti microbial levels can help to attain therapeutic concen trations. The use of biomarkers, notably procalcitonin, to guide antimicrobial therapy has been associated with reduced antimicro bial use without major risks, but further studies are still required.
Finally, eradication of the infectious source by surgi cal intervention (for example, laparotomy and explor ation) is sometimes necessary to remove any focus of infection, including iatrogenic causes such as drains or intravascular catheters.
Haemodynamic stabilization
The haemodynamic management of patients with sep sis and septic shock can be considered in four phases: salvage, optimization, stabilization and deescalation 111 . The overall goal of these four phases is to provide immedi ate haemodynamic support to prevent organ injury and shock, and then to curtail therapies in a standardized manner. The amount of fluid administered will depend on the phase of shock 111 . In the salvage phase of treatment, fluid administration should be generous 112 before monitoring is obtained. In the optimization phase, an individualized approach is needed. Signs of fluid responsiveness, including passive leg raising, can be helpful in a mechanically ventilated, deeply sedated patient. Evaluation of stroke volume changes during passive leg raising can be considered, but is not as easy. A fluid challenge technique is usually the best way to individualize fluid therapy. After the stabilization period, a deescalation phase must be conducted, in which fluid balance should become negative.
One aspect of sepsis management that is increasingly controversial is early goaldirected therapy (EGDT). In a seminal singlecentre study published in 2001, Rivers et al. 113 showed that patients with septic shock in the emergency room setting benefited from EGDT to reduce mortality, as compared with standard manage ment that did not have specific targets for determining the adequacy of response. The EGDT strategy was based on reaching a central venous oxygen saturation (ScvO 2 ) to titrate haemodynamic resuscitation using intravenous fluids, dobutamine and packed redcell transfusion to maintain a ScvO 2 of >70%. However, these positive results could not be confirmed in morerecent larger multicentre studies, perhaps because patient manage ment has improved in the control group 114 . Furthermore, the heterogeneity of patients with sepsis dictates that many different end points might be effective, making EGDT trials difficult to conduct.
When considering the immediate resuscitative phase of treatment, 'ventilation, infusion and pump' method proposed by Weil and Shubin 115 remains a useful guide. Here, hypoxaemia should be corrected and endotracheal intubation and mechanical ventilation will be needed in severe cases; noninvasive ventilation is not recom mended. On the basis of large randomized controlled trials, current guidelines recommend the use of crystal loids for fluid resuscitation and suggest the use of human albumin in cases of septic shock when patients cannot be stabilized with crystalloids alone 112 . The use of hydroxy ethyl starch in patients with sepsis has been banned by the US FDA and the European Medicines Agency owing to increased mortality; the use of other synthetic colloids is also discouraged 116 . Excessive amounts of saline solu tions should also be avoided, as hyperchloraemia can have adverse effects, especially on the kidneys 117 .
Vasoactive agents are also often required and are fre quently started alongside fluid administration to avoid prolonged hypotension, which can impair tissue perfu sion. Noradrenaline is recommended over dopamine owing to reduced adverse effects and mortality 118, 119 . Dobutamine can be and is often added to noradrena line as an inotropic agent to increase cardiac output and oxygen delivery to the tissues. Monitoring changes in blood lactate levels can help to assess the effectiveness of the resuscitation 120 . An inevitable consequence of large fluid administration and damaged endothelium is oedema. One of several approaches being investig ated to address oedema and endothelial injury is the use of selepressin, a selective vasopressin type 1a recep tor agonist that increases arterial pressure and has the potential to reduce vascular leakage and pulmonary oedema. Preclinical studies in an ovine model of sep tic shock showed clear survival benefits of selepressin over vasopressin and noradrenaline, especially when administered early 121 . Finally, appropriate ventilator support will also be required because of the high preponderance of acute lung injury. Managing appropriate lung support should be one of the core management principles for sepsis and septic shock. The overarching goal should be achieving adequate oxygenation while minimizing the fraction of inhaled oxygen and volumes inhaled, and success fully weaning the patient from the ventilator as soon as possible.
Modulation of the septic response
This exaggerated early inflammatory response has been the predominant target of early clinical interven tion using biological response modifiers in severe sep sis or septic shock. At present, there have been at least 150 clinical trials targeting either the patternrecognition receptors, the PAMPs themselves or the early cytokines or mediators produced in response to sepsis (TABLE 2) . None has proven effective to date, although several are currently still in trial. Retrospective subgroup analysis has often shown significant benefit in smaller subgroups with IL1 receptor antagonist and TNF inhibitors, but these have not been prospectively validated. Reasons for why these clinical trials have failed have been suggested to include the timing of drug administration, failure to prospectively identify patients with sepsis who would benefit from these therapies and redundancy in patient response 122 . In some patient populations, treatment with these antiinflammatory agents has actually increased mortality [123] [124] [125] , suggesting that, in some cases, endogen ous production of these mediators might be essential for protective immunity. At present, numerous anti inflammatory agents and immunostimulants are in clinical trials for sepsis and septic shock.
The sepsis team
Despite increased awareness of the importance of early diagnosis and rapid appropriate treatment of patients with sepsis, many patients still do not receive accept able early management. Patients with sepsis are highly complex, often with multiple comorbidities and rapidly changing haemodynamics. The management of such patients involves multiple elements, including invasive radiological procedures and setting up of haemo dynamic monitoring systems, blood sampling for cultures and laboratory testing, administration of antibiotics, fluid resuscitation and administration of vasoactive agents -all of which need to be started rapidly. For initial manage ment, the best way of being able to simultane ously perform all the necessary actions is for providers to be organized as a 'sepsis team' , similar to the trauma teams now widely established for the manage ment of patients with severe trauma. One member of the team would be clearly identified as the leader to direct and coordinate the overall management process. The sepsis team should be available at all times [126] [127] [128] .
Quality of life
Little is known about longterm mortality and quality of life following sepsis. In most cases, efficacy of inter vention in sepsis has been limited to inhospital index experiences, primarily 28day or 30day mortality and degree of organ injury. Only over the past decade have studies started to examine the longterm consequences of sepsis; the preliminary data are not encouraging 129, 130 . Chronic critical illness is occurring in a large proportion of patients who survive sepsis but remain hospitalized 52 ; >50% of patients in the ICU die within 3 months of sep sis and 60% have psychological disturbances 131 . Only a minority of patients return to a functional lifestyle. Few patients who survive sepsis are discharged to home; the majority of patients are discharged to longterm nursing or rehabilitative facilities. Both age and length of time in the ICU have been shown to be independent variables for longterm survival and functional recovery 129, 132, 133 . Patients >55 years of age and those who remained in the ICU for >14 days have the highest mortality rates postdischarge.
Even less is known about the longterm consequences on functional and cognitive recovery after sepsis. Intensive care specialists have recognized a syndrome in survivors of critical illness, including sepsis, termed postICU syn drome, which is characterized by insomnia, nightmares, fatigue, depression, loss of cognitive function and loss of selfesteem 134 . Almost half of the individuals who sur vived sepsis report at least three of these symptoms 135 . These individuals demonstrate cognitive deficits in ver bal learning and memory up to 2 years after the hospital discharge 136 . Interestingly, these cognitive deficits were associated with a significant reduction of left hippo campal volume compared with healthy controls. Patients with sepsis also had more lowfrequency electroencephalo gram activity indicating generalized brain dysfunction and not focal damage. Sepsis has also been known to induce posttraumatic stress disorder (PTSD) in many patients 137 . An increased incidence of PTSD in individ uals who survived sepsis is also associated with presepsis depression and delirium while in intensive care 137 . Several studies have used surveys to examine func tionality after hospital discharge (the 36Item Short Form Health Survey and the EuroQual EQ5D health questionnaire) 129, 138 . The general consensus has been that patients who survive sepsis have a prevalence of moderate tosevere cognitive impairment 10% higher than the general population. Equally important, patients who survived sepsis had a much higher frequency of new impairments than their agematched counterparts.
The underlying causes of these functional and physi cal declines are unknown, but there are many possible reasons. Primary causes might include ICUacquired weakness owing to both inactivity and immobilization, as well as from inflammation, corticosteroid and neuro muscular blockers commonly used in sepsis treatment. According to Poulson et al. 139 , in 81% of the patients who survived sepsis, loss of muscle mass at 1 year was the main cause of decreased physical function. In addi tion, direct neuronal damage and delirium may also contribute to lower physical functioning.
Outlook
Sepsis is not disappearing; in fact, although controversial, the number of patients with sepsis is probably increas ing worldwide, as are the risks associated with increased comorbidities and an ageing population in developed countries. With that said, however, there are encouraging signs. Increased recognition of the importance of early detection and rapid intervention is most likely responsible for the declines in inhospital mortality over the past dec ade. Credit for these improvements is owing in large part to the Surviving Sepsis Campaign 140 for its widespread dissemination of agreed on standard of care treatment guidelines for the management of sepsis. Furthermore, the part played by the US federal government in tying reimbursement to sepsis outcomes is likely to have a major impact on sepsis recognition moving forwards. Namely, sepsis has been recognized as an unacceptable preventable patient safety index and the Centers for Medicare and Medicaid Services are penalizing provid ers by reducing reimbursements for care. These changes in hospital reimbursement will probably be an important driving force for the implementation of procedures for recognizing sepsis and its early intervention.
Advances in treatment
Attention is being focused not only on the inhospital consequences of sepsis but also on the longterm out comes, especially in terms of functional and cognitive recovery. In this regard, treatment for individuals who survive sepsis is increasingly including physical therapy, nutritional and psychological interventions.
Modulation of the septic response. To date, no single biological response modifier is available that is currently approved for use in sepsis (TABLE 3) . The only immuno modulatory agent approved for sepsis was activated protein C (drotrecogin alfa (activated)) 141 , but this drug was withdrawn after negative postmarketing trials 142 . However, therapeutic approaches that target the early inflammatory response as well as the endothelial injury and coagulopathy are continuing. Two studies have indicated that the addition of steroids could be bene ficial in severe communityacquired pneumonia 143, 144 . In addition, extracorporeal techniques to remove DAMPs, PAMPs and inflammatory mediators are under investigation, and recent observations on the 'artificial spleen' are particularly exciting 145 . Using magnetic beads coupled to mannosebinding ligand, the biospleen was capable of reducing the magnitude of the inflammatory response by simultaneous removal of multiple PAMPs and DAMPs. Blockade of C5a with a monoclonal anti body is also currently being tested in patients with early septic organ dysfunction as a means to reduce an overly exuberant innate immune response 49 . Defining the immunological state of the patient will be crucial to the success of any biological response modi fier for sepsis. Application of immunotherapies will need to be targeted to the appropriate immunological state. For example, drugs that are aimed at stimulating innate and adaptive immunity might be contraindicated dur ing the early hyperinflammatory phase of sepsis. Thus, a means of immunophenotyping patients with sepsis is needed and many approaches, such as quantification of monocyte HLADR expression or measuring procalci tonin concentrations, are being explored. A measured approach that is based on carefully designed clinical trials in defined populations is the crucial next step in the development of these agents.
Immunostimulatory therapies.
A diverse collec tion of drugs are currently being evaluated to either block the exaggerated inflammatory and endothelial injury or restore an effective antimicrobial immune response 146 (TABLE 3). Agents that are being evaluated as immuno stimulants include leukocyte growth fac tors 147 , immuno stimulatory cytokines 148, 149 , inhibitors of negative costimulatory pathways (for example, PD1 and PDL1) 150 and unique immunomodulators, such as the thymic peptide thymosinα1 (REF. 151 ). Importantly, many of these agents have been previously used as immune adjuvants in the treatment of cancer, providing preliminary data on their safety and efficacy 152 . Perhaps the most promising potential immuno therapy in sepsis is the pleiotropic cytokine IL7 (REF. 153 ). IL7 acts broadly on cells of the adaptive immune system, driving proliferation and survival of naive and memory CD4 + and CD8 + T cells, which are relentlessly depleted in sepsis 151, 152 . Studies in patients with sarcoma 154 and HIV 155 have shown that IL7 is effective in patients with viral infections, which, together with ex vivo results, show that IL7 reverses key immuno logical defects in patients with sepsis 156 , providing a compelling case for a trial of IL7 in sepsis.
Biomarker discovery
Alongside developments in therapy, emphasis has been placed on developing biomarkers or other indices that can identify groups of patients who could benefit from individualized therapy. Indeed, given that current thera peutic approaches -targeting inflammation, immune suppression, coagulopathy, endothelial injury or organ dysfunction -must be directed at both the appropriate patient and the appropriate time, biomarkers to 'navi gate' the temporal changes in patient responses to sepsis would be invaluable.
Continued development of biomarkers that can dis tinguish sepsis from inflammation alone and that can be used as prognostic indicators, also remains an area of active investigation. Although single biomarkers have achieved predictive abilities similar to anatomical and physiological scoring systems, the future may be in multiplex approaches that use biomarkers and clinical indicators. The 'omics revolution' of genomics, tran scriptomics, proteomics, metabolomics and inter actomics is in its infancy, but preliminary studies have identified complex signatures that might not only distinguish sepsis from nonseptic critical illness but also function as prognostic indicators or indicators of response to ther apy [157] [158] [159] . Genomic signatures and genomewide associ ation studies also have the potential to identify patients who might respond to specific immunomodulatory inter ventions through the identification of alterations of speci fic pathways that can be addressed by pro inflammatory or antiinflammatory interventions 157, 158, 160 . Although there is clear evidence that genetic polymorphisms in individual inflammatory or immunosuppressant genes are associated with a varying incidence and severity of sepsis, application of personalized medicine and individ ual alleles has not yet been successful 161 . It is still too early to tell whether these multiplex approaches will prove superior to current biomarkers and clinical indices. CTLA4, cytotoxic T lymphocyte antigen 4; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HLA-DR, human leukocyte antigen-antigen D related; ICU, intensive care unit; IFNγ, interferon-γ; LAG3, lymphocyte activating gene 3; NK cell, natural killer cell; NKT cell, natural killer T cell; PDL1, programmed death ligand 1; T H 1, T helper 1; TIM3, T cell immunoglobulin and mucin-containing protein 3; T reg cell, regulatory T cell. *Acute Physiology and Chronic Health Evaluation II (APACHE II) score is a severity-of-disease classification system.
